newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

  • IGC Pharma announced Q2 2026 financial results & provided an update on its lead Alzheimer's program, IGC-AD1.
  • The Phase 2 CALMA trial reached its baseline randomization target of 146 patients & is now within six additional randomizations of closure.
  • Topline data for the CALMA trial is expected in Q4 2026 following patient follow-up, database lock, & unblinding.
  • CEO Ram Mukunda & Principal Financial Officer converted approximately $1.15 million of owed amounts into 4,274,853 shares at $0.27 per share to align with shareholders & preserve cash.
  • IGC Pharma received authorization in Colombia to synthesize & formulate psilocybin for potential neuropsychiatric research, though clinical trials require further regulatory approval.
  • Q2 2026 revenue was approximately $265 thousand, while research & development expenses rose to $1.4 million & net loss reached $3.0 million.
  • Cash & cash equivalents stood at approximately $331 thousand as of June 30, 2026, with management stating liquidity supports operations for at least twelve months.
  • The Company continues developing AI-enabled platforms AHA & MINT-AD for data harmonization & risk stratification, noting they are not approved therapeutic products.